FDA panel narrowly rejects one peptide approves two

By Crystal Simmons 25/07/2026 4 min read 43 views

The FDA advisory panel voted Friday to allow compounding pharmacies to produce the peptides epitalon and semax, while narrowly rejecting the same for emideltide. The decision follows a Thursday vote that cleared four other peptides, moving health secretary Robert F. Kennedy Jr. closer to his goal of expanding access to these unapproved compounds.

Panel votes split on safety and efficacy

During the two‑day meeting, panelists debated whether it is appropriate to let patients use medicines lacking clear safety data. FDA staff consistently recommended against granting compounding pharmacies the green light, citing insufficient clinical evidence for each peptide under review. The agency’s stance is that adding a substance to the section 503A bulk drug substances list would permit compounding without requiring manufacturers to submit safety or efficacy data.

“In the grey market, that’s not a requirement to be sent to us,” said Mary Thanh Hai, director of the Office of New Drugs. “Even getting on to the 503A compounding list, that isn’t a requirement.” Her comments highlighted the regulatory gap that could leave physicians without dosing guidance.

Panelists who voted in favor of the two peptides largely have ties to the peptide industry and were appointed by the Health and Human Services Department. They argued that they were not approving a drug, so the lack of robust clinical data should not block the recommendation. Several expressed a desire to meet patient demand.

“We’re talking about dosing and efficacy and safety, and it doesn’t look like that’s what we’ve been asked to do,” said Asare Christian, founder of wellness clinic Aether Medicine. “As a physician, my view is through the lens of the patient in front of me.”

Specific votes and the peptides involved

On Thursday, the panel voted 8‑6 to add BPC‑157 for ulcerative colitis, 8‑5 for KPV to treat wound healing and inflammatory conditions, and 8‑5 for TB‑500 also for wound healing. A separate vote of 7‑5 cleared MOTS‑c for obesity and osteoporosis.

Friday’s votes showed a 7‑4 margin for adding epitalon to the list for insomnia. The vote on semax, intended for migraines and neurological conditions such as cerebral ischemia and trigeminal neuralgia, passed 8‑5. By contrast, the panel rejected emideltide—proposed for opioid withdrawal, chronic insomnia, and narcolepsy—by a narrow 6‑7 margin.

One dissenting voice, David Pope, chief pharmacy officer at XiFin Pharmacy Solution, switched his vote on emideltide after supporting the earlier peptides. He warned of “potentially dangerous downstream consequences,” reflecting the concerns of many who remain skeptical of the compound’s safety profile.

Public comments featured strong support for semax, noting its approval in Russia and the relative amount of data compared with other peptides. Nonetheless, reviewers concluded that the existing research does not meet the agency’s standards for the specific conditions under consideration.

While the FDA is not obligated to follow the advisory panel’s recommendations, the agency typically defers to its career staff on such matters. However, the current administration’s history of allowing political considerations to influence scientific decisions raises the possibility that Secretary Kennedy or acting FDA commissioner Kyle Diamantas could intervene. Any final rule will be published for public comment before taking effect.

The outcome illustrates how the Make America Healthy Again movement is reshaping the regulatory conversation around peptide therapies. For patients seeking these compounds, the panel’s approval of epitalon and semax could translate into more pharmacies offering them, albeit without the rigorous testing that accompanies traditional drug approvals.

Clinicians may soon have to manage prescribing practices without clear dosing guidelines, a situation that could complicate patient care.

In practice, the decision may lead to a modest increase in availability at compounding pharmacies, but the lack of standardized dosing could expose patients to variable potency and uncertain side effects. Those who rely on these peptides for conditions like insomnia or migraines might find it easier to obtain them, yet they will likely face a patchwork of physician advice and limited clinical guidance.

As the rulemaking process moves forward, the FDA will open a comment period, giving stakeholders a chance to weigh in on the safety implications. The agency’s next steps will determine whether the panel’s recommendations become binding policy or remain advisory notes in an ongoing debate over unapproved peptide use.